ClinicalTrials.gg
CompletedNCT01345019Updated Nov 8, 2022Results posted

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

A Phase 3 interventional study of Denosumab and Zoledronic acid in Cancer, Hematologic Malignancies and Multiple Myeloma, sponsored by Amgen. Completed at 309 sites in 29 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-08.

Sponsored by Amgen · Phase 3, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,718
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone disease from multiple myeloma.

02

Conditions studied

  • Cancer
  • Hematologic Malignancies
  • Multiple Myeloma
  • Oncology
  • Bone Metastases
  • Multiple Myeloma Bone Lesions

Keywords

  • zoledronic acid
  • hematologic malignancies
  • SRE
  • skeletal-related event
  • blood cancer
  • lytic bone lesions
  • bone metastases
  • myeloma
  • fractures
  • spinal cord compression
  • radiation to bone
  • surgery to bone
  • bisphosphonates
  • Neoplasms, Plasma Cell
  • Paraproteinemias
  • Neoplasms
  • Neoplasm Metastasis
  • Bone Neoplasms
  • Bone Marrow Diseases
  • Blood Protein Disorders
  • Hematologic Diseases
  • multiple myeloma
  • denosumab
  • Neoplastic Processes
  • Bone Diseases
  • Diphosphonates
  • Bone Density Conservation Agents
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 1,718 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented evidence of multiple myeloma (per local assessment):
  • Monoclonal plasma cells in the bone marrow greater than or equal to 10% and/or presence of a -proven plasmacytoma, and
  • Monoclonal protein present in the serum and/or urine
  • Radiographic (X-ray, or computer tomography [CT]) evidence of at least 1 lytic bone lesion (or at least 1 focal lesion per magnetic resonance imaging [MRI])
  • Plan to receive or is receiving primary frontline anti-myeloma therapies
  • (ECOG) performance status of 0, 1, or 2
  • Age ≥ 18 years
  • Adequate organ function, as defined by the following criteria (per central or local laboratory values):

    • Serum (AST) ≤ 2.0 x (ULN)
    • Serum alanine aminotransferase ≤ (ALT) 2.0 x ULN
    • Serum total ≤ 2.0 x ULN
    • ≥ 30 mL/min
    • Serum calcium or albumin-adjusted serum calcium 2.0 mmol/L (8.0 mg/dL) and 2.9 mmol/L (11.5 mg/dL)
  • Written before any study-specific procedure is performed

Exclusion criteria

Exclusion Criteria:

  • Nonsecretory multiple myeloma based upon standard M-component criteria (ie, measurable serum/urine M-component) unless the baseline serum free light chain level is elevated
  • POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
  • Plasma cell leukemia
  • More than 30 days of previous treatment (before screening) with anti-myeloma therapy (does not include radiotherapy or a single short course of [ie, less than or equal to the equivalent of dexamethasone 60 mg/day for 4 days]).
  • Planned radiation therapy or surgery to the bone (does not include procedures performed before randomization)
  • Prior administration of denosumab
  • Use of oral bisphosphonates with a cumulative exposure of more than 1 year
  • More than 1 previous dose of IV bisphosphonate administration
  • Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw
  • Active dental or jaw condition which requires oral surgery, including tooth extraction
  • Non-healed dental/oral surgery, including tooth extraction
  • Planned invasive dental procedures
  • Evidence of any of the following conditions per subject self-report or medical chart review:

    • Any prior invasive within 5 years before randomization
    • Any non-invasive malignancy not treated with curative intent or with knownactive disease within 5 years before randomization
    • Major surgery or significant traumatic injury occurring within 4 weeks before randomization
    • Active infection with virus or virus
    • Known infection with (HIV)
    • Active infection requiring IV anti-infective therapy
  • Subject is pregnant or breast feeding, or planning to become pregnant within 5 months after end of treatment
  • Female subject of child bearing potential is not willing to use highly effective during treatment and for 5 months after the end of treatment (see section 6.3)
  • Known sensitivity to any of the products to be administered during the study (eg, mammalian derived products, calcium or vitamin D)
  • Subject is receiving or is less than 30 days since ending other experimental device or drug (no marketing authorization for any indication)
  • Subject will not be available for follow-up assessment
  • Any major medical or psychiatric disorder that in the opinion of the investigator, might prevent the subject from completing the study or interfere with the interpretation of the study results
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,718 participants (actual)

Study arms

  • Active comparator
    Zoledronic acid

    Zoledronic acid 4 mg intravenously plus placebo to denosumab subcutaniously (SC) once every 4 weeks (Q4W) in the double-blind treatment period (Since denosumab was determined to have a positive benefit:risk profile in the primary analysis of the study, per protocol, participants who were still undergoing Q4W scheduled assessments were offered open-label denosumab 120 mg SC Q4W for up to 2 years)

    Drug: Zoledronic acid · Drug: Placebo to Denosumab · Drug: Denosumab (for the open-label treatment phase)

  • Experimental
    Denosumab

    Denosumab 120 mg subcutaniously (SC) plus placebo to zoledronic acid intravenously once every 4 weeks (Q4W) in the double-blind treatment period (Since denosumab was determined to have a positive benefit:risk profile in the primary analysis of the study, per protocol, participants who were still undergoing Q4W scheduled assessments were offered open-label denosumab 120 mg SC Q4W for up to 2 years)

    Drug: Denosumab · Drug: Placebo to zoledronic acid · Drug: Denosumab (for the open-label treatment phase)

Interventions

  • Administered by subcutaneous injection once every 4 weeks.

    Also known as: XGEVA®, AMG 162

  • Administered by intravenous infusion over 15 minutes once every 4 weeks

    Also known as: Zometa®

  • DrugPlacebo to Denosumab

    Administered by subcutaneous injection once every 4 weeks.

  • DrugPlacebo to zoledronic acid

    Administered by intravenous infusion over 15 minutes once every 4 weeks

  • Administered by subcutaneous injection once every 4 weeks.

    Also known as: XGEVA®, AMG 162

06

What researchers measure

Primary outcomes

  1. Time to First On-study Skeletal Related Event

    A skeletal-related event (SRE) is defined as one of the following: pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression. Time to first on-study SRE is defined as the time interval (in days) from the randomization date to the date of first occurrence of on-study SRE. If there was no known event, and the participant was monitored for any one of the four SRE components, time to first on-study SRE was censored at the end of the treatment phase date or the primary analysis data cut-off date, whichever came first.

    Time frame: From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.

  2. Percentage of Participants With an On-study Skeletal Related Event

    A skeletal-related event (SRE) is defined as one of the following: pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression.

    Time frame: From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.

  3. Kaplan-Meier Estimate of Percentage of Participants With an On-study Skeletal Related Event

    A skeletal-related event (SRE) is defined as one of the following: pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression.

    Time frame: From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively. The Kaplan-Meier estimate at weeks 25, 49 and 109 is reported.

Secondary outcomes

  1. Time to First On-study Skeletal Related Event - Superiority Analysis

    A skeletal-related event (SRE) is defined as one of the following: pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression. Time to first on-study SRE is defined as the time interval (in days) from the randomization date to the date of first occurrence of on-study SRE. If there was no known event, and the participant was monitored for any one of the four SRE components, time to first on-study SRE was censored at the end of the treatment phase date or the primary analysis data cut-off date, whichever came first.

    Time frame: From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.

  2. Time to First and Subsequent On-Study Skeletal Related Event - Number of Events Per Patient

    A skeletal-related event (SRE) is defined as one of the following: pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression. Time to first on-study SRE is defined as the time interval (in days) from the randomization date to the date of first occurrence of on-study SRE. Time to a subsequent SRE is defined, similarly to the time to first on-study SRE, as the time interval from the randomization date to the date of a subsequent occurrence of on-study SRE, which had to be at least 21 days after the previous SRE. A multiple event analysis was used, which accounts for both the absolute number of SREs and for the time between two consecutive events, and therefore, provides a more sensitive assessment of the risk of experiencing an SRE. The average number of events per patient is reported.

    Time frame: From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.

  3. Time to First and Subsequent On-Study Skeletal Related Event - Number of Events

    A skeletal-related event (SRE) is defined as one of the following: pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression. Time to first on-study SRE is defined as the time interval (in days) from the randomization date to the date of first occurrence of on-study SRE. Time to a subsequent SRE is defined, similarly to the time to first on-study SRE, as the time interval from the randomization date to the date of a subsequent occurrence of on-study SRE, which had to be at least 21 days after the previous SRE. A multiple event analysis was used, which accounts for both the absolute number of SREs and for the time between two consecutive events, and therefore, provides a more sensitive assessment of the risk of experiencing an SRE. The total number of events is reported.

    Time frame: From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.

  4. Overall Survival

    Overall survival was defined as the time interval (in days) from the randomization date to the date of death. If a participant was still alive at the primary analysis data cut-off date or was lost to follow-up by the primary analysis data cut-off date, survival time was censored at their last contact date or the primary analysis data cut-off date, whichever was first.

    Time frame: From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.

  5. Percentage of Participants Who Died

    Time frame: From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.

07

Results

Posted Mar 7, 2018

Participant flow

This study was conducted at 259 centers across 29 countries in Europe, North America, Asia, Australia/New Zealand, and Japan. Participants were enrolled from 17 May 2012 to 29 March 2016.

Blinded Treatment Phase
Participant flow — Blinded Treatment Phase
MilestoneZoledronic AcidDenosumab
Started859859
Received treatment852850
Completed541555
Not completed318304
Withdrew: Death147137
Withdrew: Withdrawal by subject103112
Withdrew: Completed survival follow-up219
Withdrew: Disease progression1210
Withdrew: Adverse event613
Withdrew: Administrative decision108
Withdrew: Noncompliance53
Withdrew: Ineligibility determined16
Withdrew: Protocol deviation50
Withdrew: Other, not specified23
Withdrew: Lost to follow-up63
Open Label Treatment Phase
Participant flow — Open Label Treatment Phase
MilestoneZoledronic AcidDenosumab
Started418426
Completed227233
Not completed191193
Withdrew: Death4948
Withdrew: Withdrawal by subject4947
Withdrew: Adverse event3051
Withdrew: Administrative decision3015
Withdrew: Disease progression1718
Withdrew: Noncompliance54
Withdrew: Lost to follow-up12
Withdrew: Pregnancy10
Withdrew: Other, not specified97
Withdrew: Protocol violation01

Outcome measures

PrimaryTime to First On-study Skeletal Related Event

A skeletal-related event (SRE) is defined as one of the following: pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression. Time to first on-study SRE is defined as the time interval (in days) from the randomization date to the date of first occurrence of on-study SRE. If there was no known event, and the participant was monitored for any one of the four SRE components, time to first on-study SRE was censored at the end of the treatment phase date or the primary analysis data cut-off date, whichever came first.

Time frame:
From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.
Reported as:
Median · days
Time to First On-study Skeletal Related Event
daysZoledronic AcidDenosumab
Time to First On-study Skeletal Related Event730.0 (504.0 to 1014.0)695.0 (448.0 to NA)
Statistical analysis
  • Zoledronic Acid vs Denosumab · Cox proportional hazards model · p = 0.010 · Hazard ratio (hr): 0.98 · 95% CI 0.85 to 1.14A hazard ratio (denosumab:zoledronic acid) \< 1 favors denosumab
PrimaryPercentage of Participants With an On-study Skeletal Related Event

A skeletal-related event (SRE) is defined as one of the following: pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression.

Time frame:
From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.
Reported as:
Number · percentage of participants
Percentage of Participants With an On-study Skeletal Related Event
percentage of participantsZoledronic AcidDenosumab
Percentage of Participants With an On-study Skeletal Related Event44.6 (41.3 to 47.9)43.8 (40.5 to 47.1)
PrimaryKaplan-Meier Estimate of Percentage of Participants With an On-study Skeletal Related Event

A skeletal-related event (SRE) is defined as one of the following: pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression.

Time frame:
From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively. The Kaplan-Meier estimate at weeks 25, 49 and 109 is reported.
Reported as:
Number · percentage of participants
Kaplan-Meier Estimate of Percentage of Participants With an On-study Skeletal Related Event
percentage of participantsZoledronic AcidDenosumab
At Week 2536.5 (33.3 to 39.9)35.9 (32.7 to 39.3)
At Week 4943.2 (39.7 to 46.8)43.7 (40.2 to 47.3)
At Week 10950.6 (46.6 to 54.6)50.5 (46.6 to 54.5)
SecondaryTime to First On-study Skeletal Related Event - Superiority Analysis

A skeletal-related event (SRE) is defined as one of the following: pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression. Time to first on-study SRE is defined as the time interval (in days) from the randomization date to the date of first occurrence of on-study SRE. If there was no known event, and the participant was monitored for any one of the four SRE components, time to first on-study SRE was censored at the end of the treatment phase date or the primary analysis data cut-off date, whichever came first.

Time frame:
From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.
Reported as:
Median · days
Time to First On-study Skeletal Related Event - Superiority Analysis
daysZoledronic AcidDenosumab
Time to First On-study Skeletal Related Event - Superiority Analysis730.0 (504.0 to 1014.0)695.0 (448.0 to NA)
Statistical analysis
  • Zoledronic Acid vs Denosumab · Log Rank · p = 0.82Based on a log rank test stratified by randomization stratification factors.
SecondaryTime to First and Subsequent On-Study Skeletal Related Event - Number of Events Per Patient

A skeletal-related event (SRE) is defined as one of the following: pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression. Time to first on-study SRE is defined as the time interval (in days) from the randomization date to the date of first occurrence of on-study SRE. Time to a subsequent SRE is defined, similarly to the time to first on-study SRE, as the time interval from the randomization date to the date of a subsequent occurrence of on-study SRE, which had to be at least 21 days after the previous SRE. A multiple event analysis was used, which accounts for both the absolute number of SREs and for the time between two consecutive events, and therefore, provides a more sensitive assessment of the risk of experiencing an SRE. The average number of events per patient is reported.

Time frame:
From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.
Reported as:
Number · events/patient
Time to First and Subsequent On-Study Skeletal Related Event - Number of Events Per Patient
events/patientZoledronic AcidDenosumab
Time to First and Subsequent On-Study Skeletal Related Event - Number of Events Per Patient0.660.66
Statistical analysis
  • Zoledronic Acid vs Denosumab · Andersen-Gill model · p = 0.84 · Rate ratio: 1.01 · 95% CI 0.89 to 1.15A rate ratio (denosumab:zoledronic acid) \< 1 favors denosumab.
SecondaryTime to First and Subsequent On-Study Skeletal Related Event - Number of Events

A skeletal-related event (SRE) is defined as one of the following: pathologic fracture (vertebral or non-vertebral), radiation therapy to bone (including the use of radioisotopes), surgery to bone, or spinal cord compression. Time to first on-study SRE is defined as the time interval (in days) from the randomization date to the date of first occurrence of on-study SRE. Time to a subsequent SRE is defined, similarly to the time to first on-study SRE, as the time interval from the randomization date to the date of a subsequent occurrence of on-study SRE, which had to be at least 21 days after the previous SRE. A multiple event analysis was used, which accounts for both the absolute number of SREs and for the time between two consecutive events, and therefore, provides a more sensitive assessment of the risk of experiencing an SRE. The total number of events is reported.

Time frame:
From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.
Reported as:
Number · skeletal-related events
Time to First and Subsequent On-Study Skeletal Related Event - Number of Events
skeletal-related eventsZoledronic AcidDenosumab
Time to First and Subsequent On-Study Skeletal Related Event - Number of Events565565
SecondaryOverall Survival

Overall survival was defined as the time interval (in days) from the randomization date to the date of death. If a participant was still alive at the primary analysis data cut-off date or was lost to follow-up by the primary analysis data cut-off date, survival time was censored at their last contact date or the primary analysis data cut-off date, whichever was first.

Time frame:
From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.
Reported as:
Median · days
Overall Survival
daysZoledronic AcidDenosumab
Overall SurvivalNA (NA to NA)1507.0 (NA to NA)
Statistical analysis
  • Zoledronic Acid vs Denosumab · Cox proportional hazards model · p = 0.41 · Hazard ratio (hr): 0.90 · 95% CI 0.70 to 1.16A hazard ratio (denosumab:zoledronic acid) \< 1 favors denosumab.
SecondaryPercentage of Participants Who Died
Time frame:
From randomization until the primary analysis data cut-off date of 19 July 2016 (per protocol); median time on study was 17.6 and 17.3 months in each treatment group respectively.
Reported as:
Number · percentage of participants
Percentage of Participants Who Died
percentage of participantsZoledronic AcidDenosumab
Percentage of Participants Who Died15.0 (12.6 to 17.4)14.1 (11.8 to 16.4)

Adverse events

Collected over DB (double-blind treatment phase): adverse events (AEs) were from 1st dose of study drug to the later of 30 days after last dose or end of treatment phase. OL (open-label treatment phase): AEs were from 1st dose of OL study drug to end of study. Median months on study drug: 18.4 (zoledronic acid [ZA]) and 19.4 (Denosumab [Dmab]) in DB; 23.2 (ZA/Dmab) and 23.0 (Dmab/Dmab) in OL.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DB: Zoledronic Acid—447/852 (52.5%)778/852 (91.3%)
DB: Denosumab—434/850 (51.1%)757/850 (89.1%)
OL: Zoledronic Acid / Denosumab—159/418 (38%)313/418 (74.9%)
OL: Denosumab / Denosumab—156/426 (36.6%)312/426 (73.2%)
Most frequent serious events
Showing 10 of 683
Most frequent serious events
EventDB: Zoledronic AcidDB: DenosumabOL: Zoledronic Acid / DenosumabOL: Denosumab / Denosumab
PneumoniaInfections and infestations82/85279/85034/41831/426
PyrexiaGeneral disorders28/85224/8502/4184/426
AnaemiaBlood and lymphatic system disorders26/85212/8505/4188/426
Febrile neutropeniaBlood and lymphatic system disorders25/85223/8507/4186/426
SepsisInfections and infestations24/85219/8508/41811/426
Osteonecrosis of jawMusculoskeletal and connective tissue disorders13/85218/85011/41812/426
Acute kidney injuryRenal and urinary disorders24/85217/8508/4182/426
Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)16/85218/8503/41810/426
Respiratory tract infectionInfections and infestations8/8527/8508/4185/426
Pulmonary embolismRespiratory, thoracic and mediastinal disorders13/85216/8505/4183/426
Most frequent other events
Showing 10 of 65
Most frequent other events
EventDB: Zoledronic AcidDB: DenosumabOL: Zoledronic Acid / DenosumabOL: Denosumab / Denosumab
DiarrhoeaGastrointestinal disorders301/852304/85073/41857/426
NauseaGastrointestinal disorders274/852284/85032/41835/426
FatigueGeneral disorders215/852206/85043/41838/426
ConstipationGastrointestinal disorders214/852207/85019/41827/426
PyrexiaGeneral disorders210/852182/85030/41844/426
AnaemiaBlood and lymphatic system disorders185/852208/85051/41862/426
Back painMusculoskeletal and connective tissue disorders181/852194/85046/41856/426
ThrombocytopeniaBlood and lymphatic system disorders151/852174/85027/41827/426
NeutropeniaBlood and lymphatic system disorders166/852173/85040/41851/426
CoughRespiratory, thoracic and mediastinal disorders170/852159/85051/41847/426

Baseline characteristics

Age, Continuous
Age, Continuous(years)Zoledronic AcidDenosumabTotal
Mean63.3 ± 10.563.5 ± 10.663.4 ± 10.6
Age, Customized
Age, Customized(Participants)Zoledronic AcidDenosumabTotal
< 65 years464472936
≥ 65 years395387782
Sex: Female, Male
Sex: Female, Male(Participants)Zoledronic AcidDenosumabTotal
Female386397783
Male473462935
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Zoledronic AcidDenosumabTotal
Hispanic or Latino353570
Not Hispanic or Latino8198231642
Unknown or Not Reported516
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Zoledronic AcidDenosumabTotal
White6997111410
Asian101107208
Black or African American362965
Other191029
American Indian or Alaska Native303
Native Hawaiian or Other Pacific Islander011
Multiracial011
Missing101
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Zoledronic AcidDenosumabTotal
0 (Fully active)259263522
1 (Restricted but ambulatory)413400813
2 (Ambulatory but unable to work)187196383
Skeletal Related Event History
Skeletal Related Event History(participants)Zoledronic AcidDenosumabTotal
Any Skeletal Related Event5775671144
Pathological fracture463479942
Spinal cord compression11592207
Radiation therapy to bone139118257
Surgery to bone144142286
Summary of Randomization Stratifications
Summary of Randomization Stratifications(participants)Zoledronic AcidDenosumabTotal
Intent to undergo PBSC transplantation: Yes465465930
Intent to undergo PBSC transplantation: No394394788
Anti-myeloma agent utilized/planned: Novel8218191640
Anti-myeloma agent utilized/planned: Non-novel384078
ISS stage at diagnosis: I268263531
ISS stage at diagnosis: II313319632
ISS stage at diagnosis: III278277555
Previous SRE : Yes484481965
Previous SRE : No375378753
Region: Japan182442
Region: Non-Japan8418351676
08

Study locations

309 sites
  • Research Site
    Tucson, Arizona 85704, United States
  • Research Site
    Fayetteville, Arkansas 72703, United States
  • Research Site
    Anaheim, California 92801, United States
  • Research Site
    Campbell, California 95008, United States
  • Research Site
    Encinitas, California 92024, United States
  • Research Site
    Fresno, California 93720, United States
  • Research Site
    Pleasant Hill, California 94523, United States
  • Research Site
    Santa Barbara, California 93105, United States
  • Research Site
    Santa Maria, California 93454, United States
  • Research Site
    Stamford, Connecticut 06902, United States
  • Research Site
    Washington, District of Columbia 20007, United States
  • Research Site
    Washington, District of Columbia 20010, United States
  • Research Site
    Boynton Beach, Florida 33426, United States
  • Research Site
    Boynton Beach, Florida 33435, United States
  • Research Site
    Jacksonville, Florida 32256, United States
  • Research Site
    Columbus, Georgia 31904, United States
  • Research Site
    Savannah, Georgia 31405, United States
  • Research Site
    Chicago, Illinois 60612, United States
  • Research Site
    Joliet, Illinois 60435, United States
  • Research Site
    Maywood, Illinois 60153, United States
  • Research Site
    Niles, Illinois 60714, United States
  • Research Site
    Skokie, Illinois 60076, United States
  • Research Site
    Skokie, Illinois 60077, United States
  • Research Site
    Anderson, Indiana 46016, United States
  • Research Site
    Fort Wayne, Indiana 46845, United States
  • Research Site
    Indianapolis, Indiana 46202, United States
  • Research Site
    Ames, Iowa 50010, United States
  • Research Site
    Iowa City, Iowa 52242, United States
  • Research Site
    Paducah, Kentucky 42003, United States
  • Research Site
    New Orleans, Louisiana 70121, United States
  • Research Site
    Scarborough, Maine 04074, United States
  • Research Site
    Baltimore, Maryland 21204, United States
  • Research Site
    Baltimore, Maryland 21229, United States
  • Research Site
    Baltimore, Maryland 21237, United States
  • Research Site
    Bethesda, Maryland 20817, United States
  • Research Site
    Westminster, Maryland 21157, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Danvers, Massachusetts 01923, United States
  • Research Site
    Fairhaven, Massachusetts 02719, United States
  • Research Site
    Detroit, Michigan 48201, United States
  • Research Site
    Lansing, Michigan 48910, United States
  • Research Site
    Jackson, Mississippi 39216, United States
  • Research Site
    Springfield, Missouri 65806, United States
  • Research Site
    Billings, Montana 59101, United States
  • Research Site
    Lincoln, Nebraska 68506, United States
  • Research Site
    Omaha, Nebraska 68198, United States
  • Research Site
    North Las Vegas, Nevada 89086, United States
  • Research Site
    Hackensack, New Jersey 07601, United States
  • Research Site
    Lake Success, New York 11042, United States
  • Research Site
    New York, New York 10021, United States
  • Research Site
    Rochester, New York 14621, United States
  • Research Site
    Fayetteville, North Carolina 28304, United States
  • Research Site
    Goldsboro, North Carolina 27534, United States
  • Research Site
    High Point, North Carolina 27262, United States
  • Research Site
    Bismarck, North Dakota 58501, United States
  • Research Site
    Oklahoma City, Oklahoma 73120-8345, United States
  • Research Site
    Hershey, Pennsylvania 17033, United States
  • Research Site
    Philadelphia, Pennsylvania 19106, United States
  • Research Site
    Philadelphia, Pennsylvania 19140, United States
  • Research Site
    Philadelphia, Pennsylvania 19141, United States
  • Research Site
    West Reading, Pennsylvania 19611, United States
  • Research Site
    Charleston, South Carolina 29406, United States
  • Research Site
    Charleston, South Carolina 29414, United States
  • Research Site
    Greenville, South Carolina 29615, United States
  • Research Site
    Aberdeen, South Dakota 57401, United States
  • Research Site
    Rapid City, South Dakota 57701, United States
  • Research Site
    Sioux Falls, South Dakota 57105, United States
  • Research Site
    Watertown, South Dakota 57201, United States
  • Research Site
    Memphis, Tennessee 38120, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Lubbock, Texas 79415, United States
  • Research Site
    Salt Lake City, Utah 84106, United States
  • Research Site
    Christiansburg, Virginia 24073, United States
  • Research Site
    Spokane, Washington 99208, United States
  • Research Site
    Tacoma, Washington 98405, United States
  • Research Site
    Morgantown, West Virginia 26506, United States
  • Research Site
    Minocqua, Wisconsin 54548, United States
  • Research Site
    Wauwatosa, Wisconsin 53226, United States
  • Research Site
    Liverpool, New South Wales 2170, Australia
  • Research Site
    Tweed Heads, New South Wales 2485, Australia
  • Research Site
    Douglas, Queensland 4814, Australia
  • Research Site
    South Brisbane, Queensland 4101, Australia
  • Research Site
    Hobart, Tasmania 7000, Australia
  • Research Site
    Clayton, Victoria 3168, Australia
  • Research Site
    Epping, Victoria 3076, Australia
  • Research Site
    Malvern, Victoria 3144, Australia
  • Research Site
    Parkville, Victoria 3050, Australia
  • Research Site
    Prahran, Victoria 3181, Australia
  • Research Site
    Graz, 8036, Austria
  • Research Site
    Innsbruck, 6020, Austria
  • Research Site
    Krems an der Donau, 3500, Austria
  • Research Site
    Salzburg, 5020, Austria
  • Research Site
    Wels, 4600, Austria
  • Research Site
    Wien, 1090, Austria
  • Research Site
    Wien, 1140, Austria
  • Research Site
    Pleven, 5800, Bulgaria
  • Research Site
    Plovdiv, 4002, Bulgaria
  • Research Site
    Sofia, 1407, Bulgaria
  • Research Site
    Sofia, 1431, Bulgaria

Showing the first 100 of 309 sites across 29 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Raje N, Roodman GD, Willenbacher W, Shimizu K, Garcia-Sanz R, Terpos E, Kennedy L, Sabatelli L, Intorcia M, Hechmati G. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America. J Med Econ. 2018 May;21(5):525-536. doi: 10.1080/13696998.2018.1445634. Epub 2018 Mar 5. PubMed 29480139 ↗
  • Raje N, Terpos E, Willenbacher W, Shimizu K, Garcia-Sanz R, Durie B, Legiec W, Krejci M, Laribi K, Zhu L, Cheng P, Warner D, Roodman GD. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018 Mar;19(3):370-381. doi: 10.1016/S1470-2045(18)30072-X. Epub 2018 Feb 9. PubMed 29429912 ↗
  • Huang SY, Yoon SS, Shimizu K, Chng WJ, Chang CS, Wong RS, Gao S, Wang Y, Gordon SW, Glennane A, Min CK. Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study-Asian Subgroup Analysis. Adv Ther. 2020 Jul;37(7):3404-3416. doi: 10.1007/s12325-020-01395-x. Epub 2020 Jun 10. PubMed 32524500 ↗
  • Terpos E, Raje N, Croucher P, Garcia-Sanz R, Leleu X, Pasteiner W, Wang Y, Glennane A, Canon J, Pawlyn C. Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study. Blood Adv. 2021 Feb 9;5(3):725-736. doi: 10.1182/bloodadvances.2020002378. PubMed 33560384 ↗

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2012 to primary completion in Jul 2016, 50 months.

Results were first posted in Mar 2018, 1 year 7 months after primary completion. A results delay was requested in Mar 2017.

Of 119 industry-sponsored phase 3 interventional studies under Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 72. This study's 50 months is above that.

Counting every sponsor, half of 202 studies reached it within 50 months; a quarter within 33 and three quarters within 84.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2011
First posted
Apr 29, 2011
StartActual
May 17, 2012
Primary completionActual
Jul 19, 2016
CompletionActual
Mar 29, 2019
Results delay requested
Mar 21, 2017
Results first posted
Mar 7, 2018
Last update
Nov 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01345019
Lead sponsor
Amgen
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Apr 29, 2011
Start date
May 17, 2012
Primary completion
Jul 19, 2016
Completion
Mar 29, 2019
Results posted
Mar 7, 2018
Last update
Nov 8, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion